CytoSorbents Corporation (CTSO)

[Good Sport]

CytoSorbents Highlights New Clinical Data from Current Studies at the Live 42nd International Symposium on Intensive Care & Emergency Medicine (ISICEM)
March 22, 2023 08:09 ET | Source: CytoSorbents


PRINCETON, N.J., March 22, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced its scientific program for the 42nd International Symposium on Intensive Care & Emergency Medicine (ISICEM 2023) Congress being held this week in Brussels, Belgium. Importantly, new data from some of the latest studies will be presented on Thursday, March 23, 2023, during a live streamed symposium entitled “Hemoadsorption with CytoSorb® – New evidence from current studies” from 12:30-1:30 PM CET (7:30-8:30AM EDT).


Session: “Hemoadsorption with CytoSorb® – New evidence from current studies”
Time: 12:30-1:30 PM CET (7:30-8:30AM EDT)
Place: Copper Hall, Brussels Congress Center
Registration: Live streamed webinar



https://www.globenewswire.com/news-release/2023/03/22/2632168/0/en/CytoSorbents-Highlights-New-Clinical-Data-from-Current-Studies-at-the-Live-42nd-International-Symposium-on-Intensive-Care-Emergency-Medicine-ISICEM.html


----------------------------------------------------------------------------------------------------------------